D-NOME: A Deep-Tech Startup Democratizing Molecular Diagnostics with AI

D-NOME: A Deep-Tech Startup Democratizing Molecular Diagnostics with AI – Molecular diagnostics is a branch of medical testing that analyzes the molecular structure of biological samples, such as DNA, RNA, or proteins, to detect and diagnose diseases, infections, and mutations. Molecular diagnostics can provide accurate, rapid, and personalized information that can help in prevention, treatment, and management of various health conditions, such as cancer, infectious diseases, genetic disorders, and antimicrobial resistance.

However, molecular diagnostics also faces many challenges, such as high cost, complexity, and accessibility. The current methods of molecular diagnostics require expensive and sophisticated equipment, such as PCR machines, sequencers, and microarrays, that are not widely available or affordable for many people, especially in low-resource settings. Moreover, the current methods of molecular diagnostics also require trained personnel, cold-chain transportation, and laboratory infrastructure, that add to the operational and logistical difficulties.

D-NOME

Details of the startup:

  • CITY : Hyderabad
  • STATE : Telangana
  • STARTED IN : 2021
  • FOUNDERS : Divya Sriram and Sujoy Deb
  • NUMBER OF INVESTORS : 6
  • LATEST ROUND INVESTMENT : ₹122.24M
  • TOTAL INVESTMENT : ₹126.31M
  •   TOTAL SECURED LOANS AVAILED : Nil

You can find their website here.

To overcome these challenges, a startup called D-NOME has developed a novel technology that democratizes molecular diagnostics with AI. D-NOME is a deep-tech startup from India that uses cell-free synthetic biotechnology and machine learning to enable rapid, accurate, and scalable diagnostics and other platform applications. D-NOME’s flagship product is a deviceless, room-temperature, and paper-based molecular diagnostic test that can detect and quantify any target molecule from any biological sample within minutes.

We will explore how D-NOME works, what benefits it provides to healthcare and life sciences, and what are its future plans.

Primary Healthtech: Revolutionizing Diagnostics with Mobilab

How D-NOME Works

D-NOME is a cloud-based platform that uses AI to provide molecular diagnostics solutions in the following steps:

  • Sample Collection: D-NOME can collect any biological sample, such as blood, saliva, urine, or swab, using a simple and non-invasive method. D-NOME does not require any sample preparation, extraction, or amplification, as it uses cell-free synthetic biotechnology to directly access the target molecules from the sample.
  • Test Execution: D-NOME can execute the molecular diagnostic test using a paper-based device that contains synthetic biological circuits, such as DNA, RNA, or proteins, that are designed to bind and react with the target molecules from the sample. D-NOME can detect and quantify any target molecule, such as DNA, RNA, protein, or metabolite, using a colorimetric or fluorescent signal that is generated by the synthetic biological circuits.
  • Result Interpretation: D-NOME can interpret the molecular diagnostic result using a smartphone app that captures and analyzes the image of the paper-based device. D-NOME uses machine learning and computer vision to measure and quantify the signal intensity and compare it with a reference database to provide a diagnosis and a confidence score. D-NOME can also provide additional information and recommendations based on the result, such as treatment options, disease progression, or drug resistance.
  • Data Integration: D-NOME can integrate the molecular diagnostic data with existing systems and applications, such as electronic health records, telemedicine platforms, and epidemiological databases, to enable faster and better decision making for healthcare and life sciences. D-NOME can also generate reports and insights based on the data and provide feedback and suggestions for improving the test performance and accuracy.
Module Innovations: Revolutionizing Point-of-Care Diagnostics with Nanotechnology and Speed

Benefits of D-NOME

D-NOME claims to provide the following benefits to healthcare and life sciences who use its platform:

  • Increased Accessibility: By using a deviceless, room-temperature, and paper-based molecular diagnostic test, D-NOME can make molecular diagnostics accessible and affordable for everyone, especially in low-resource settings. D-NOME can also enable point-of-care and at-home testing, as it does not require any laboratory infrastructure or trained personnel.
  • Reduced Time: By using a cell-free synthetic biotechnology and machine learning, D-NOME can reduce the time and complexity of molecular diagnostics. D-NOME can provide a molecular diagnostic result within minutes, instead of hours or days, as it does not require any sample preparation, extraction, or amplification. D-NOME can also provide a diagnosis and a confidence score, instead of a raw signal, as it uses machine learning and computer vision to interpret the result.
  • Improved Accuracy: By using a synthetic biological circuit and a smartphone app, D-NOME can improve the accuracy and reliability of molecular diagnostics. D-NOME can detect and quantify any target molecule, regardless of its type, size, or concentration, using a colorimetric or fluorescent signal that is generated by the synthetic biological circuit. D-NOME can also measure and quantify the signal intensity and compare it with a reference database to provide a diagnosis and a confidence score, using machine learning and computer vision to analyze the image of the paper-based device.
  • Enhanced Impact: By using a cloud-based and scalable platform, D-NOME can enhance the impact and value of molecular diagnostics for healthcare and life sciences. D-NOME can integrate the molecular diagnostic data with existing systems and applications, such as electronic health records, telemedicine platforms, and epidemiological databases, to enable faster and better decision making for healthcare and life sciences. D-NOME can also generate reports and insights based on the data and provide feedback and suggestions for improving the test performance and accuracy.
Agatsa: Revolutionizing Healthcare with AI-Powered Diagnostics in Your Pocket

Future Plans of D-NOME

D-NOME was founded in 2021 by Dr. Aniruddha Datta, Dr. Suman Chakraborty, Divya Sriram and Sujoy Deb, who are experts in synthetic biology, microfluidics, and machine learning, respectively. The startup has raised over Rs 10 crore in funding from investors such as Arkam Ventures, 021 Capital, India Quotient, and Better Capital. The startup has also won several awards and recognitions such as the BIRAC BIG Grant, the DBT-AMR Grant, and the Elevate 100 Award.

D-NOME currently has over 10 patents and publications in the field of cell-free synthetic biotechnology and machine learning. The startup is also collaborating with various academic and industry partners, such as IIT Kharagpur, CCMB Hyderabad, and Apollo Hospitals, to validate and deploy its molecular diagnostic tests for various applications, such as COVID-19, tuberculosis, cancer, and antimicrobial resistance.

D-NOME aims to become a global leader in molecular diagnostics with AI, by developing and delivering innovative and impactful solutions for various health conditions, infections, and mutations. D-NOME also plans to leverage its cell-free synthetic biotechnology and machine learning platform to create new and exciting applications in the domains of healthcare and life sciences, such as therapeutics, biosensors, and biomanufacturing. D-NOME’s vision is to democratize molecular diagnostics with AI and empower millions of people across the world with timely and personalized information about their health and well-being.

What are your thoughts on D-NOME’s technology and its potential impact on healthcare? Share your perspective in the comments below!

You May Also Like

More From Author

+ There are no comments

Add yours